Fennec Pharmaceuticals Inc (NASDAQ:FENC) reported its fourth quarter and full-year 2025 financial results, delivering record annual revenue for its sole commercial product, PEDMARK®. However, the company's bottom-line results fell short of Wall Street expectations, leading to a negative reaction in pre-market trading.
Earnings Miss Amidst Strong Sales Growth
The core narrative from the earnings release is one of robust commercial execution contrasted with a wider-than-expected quarterly loss. For the fourth quarter of 2025, Fennec reported net product sales of $13.8 million, a significant 75% increase over the $7.9 million reported in the same period last year. This impressive growth contributed to full-year 2025 net product sales of $44.6 million, representing 50% year-over-year growth.
Despite this top-line strength, the company's earnings per share (EPS) disappointed. Fennec reported a non-GAAP EPS of -$0.11 for Q4 2025. This result missed the consensus analyst estimate, which had projected a small profit of $0.04 per share. The revenue figure of $13.78 million also came in slightly below the analyst estimate of $14.27 million.
- Reported Q4 2025 Revenue: $13.78 million
- Analyst Estimate for Q4 2025 Revenue: $14.27 million
- Reported Q4 2025 Non-GAAP EPS: -$0.11
- Analyst Estimate for Q4 2025 Non-GAAP EPS: $0.04
Market Reaction
The market's immediate response to the earnings miss was negative. In pre-market trading following the release, Fennec's stock was down approximately 6%. This price action suggests investors were focused on the earnings shortfall and potentially concerned about the company's path to profitability, even as sales of PEDMARK show accelerating growth.
Business Update and Forward Outlook
The press release highlighted the commercial momentum behind PEDMARK, a drug designed to reduce the risk of hearing loss (ototoxicity) in pediatric cancer patients undergoing cisplatin chemotherapy. The company emphasized the expansion of its commercial field force and its "Fennec HEARS" patient support program as key drivers behind the record annual sales.
Management did not provide specific financial guidance for the coming year in the summarized release. However, current analyst projections offer a benchmark for expectations. Analysts are forecasting significant growth to continue, with estimates for full-year 2026 sales reaching approximately $78.5 million. For the upcoming first quarter of 2026, the consensus sales estimate stands at $17.57 million.
- Analyst Sales Estimate for Q1 2026: $17.57 million
- Analyst Sales Estimate for Full-Year 2026: $78.5 million
Summary of Key Elements
The earnings report from Fennec Pharmaceuticals presents a mixed but fundamentally growth-oriented picture:
- Record Commercial Performance: Full-year PEDMARK sales grew 50% to $44.6 million, with Q4 sales surging 75% year-over-year.
- Earnings Shortfall: The company reported a quarterly loss per share that was worse than analysts had anticipated, overshadowing the strong revenue growth.
- Investment in Growth: The company is actively investing in its commercial infrastructure to support the adoption of PEDMARK in the pediatric oncology market.
- Market Focus on Profitability: The immediate negative stock reaction indicates the market is weighing the strong sales trajectory against the timeline and costs associated with achieving sustained profitability.
For a detailed look at Fennec's historical earnings performance and future analyst projections, you can review the earnings history and analyst estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.